Tango Therapeutics
Watchlist
Tango Therapeutics (TNGX) in Pivotal Point Check: Outstanding Study Data in Pancreatic Cancer - Leerink Sees Over 50% Upside Potential!
Reading Time: 2 minutes
Outstanding Study Data: Biotech stock surges over 53%, driven by a 92% response rate in pancreatic cancer. Strategic Focus Shifts: Management concentrates all resources on promising combination therapies. Analysts Double Price Target: The investment bank Leerink raises the price target from $28 to $55 and sees a significant turning point. Tango Therapeutics is a clinical-stage biotechnology company focused on precision medicine against cancer. The stock experienced a massive jump of 53% on June 8. This steep rise followed the release...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
